Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease

L. Devizzi, L. Maffioli, V. Bonfante, S. Viviani, L. Balzarini, M. Gasparini, P. Valagussa, E. Bombardieri, A. Santoro, G. Bonadonna

Research output: Contribution to journalArticle

Abstract

Background: In patients with Hodgkin's disease, the use of gallium-67 scintigraphy (Ga-67) compared to conventional staging and restaging techniques is still controversial. In particular in a combined modality treatment with chemotherapy and radiotherapy given in sequence, its role in detecting active disease after chemotherapy may be useful in planning the subsequent radiotherapeutic strategy. Patients and methods: From March 1990 to September 1994, 125 patients with previously untreated histologically proven Hodgkin's disease were enrolled in two different prospective trials according to clinical stage. Staging procedures included Ga-67, chest- abdominal computed tomography (CT), and/or magnetic resonance (MR). All three tests were performed in 53 patients at staging and in 47 at restaging. Results of Ga-67 at staging were compared to conventional procedures or pathological findings. Results of Ga-67, CT scan, and MR at restaging were compared to disease outcome during the follow-up. Finally a cost/benefit ratio for each test was determined. Results: At staging, Ga-67 showed lower sensitivity than CT and MR (90 vs. 96 and 100%, respectively) because of the number of false-negative images. Nevertheless, by using both CT and Ga-67 scan, the sensitivity is equal to that observed with MR (100%). At restaging, Ga-67 is superior to CT scan and equivalent to MR in detecting true negative patients (specificity: 98% vs. 45% vs. 92%). Conclusion: As a single technique, Ga-67 scan cannot substitute for CT scan or MR in staging patients with Hodgkin's disease. Nevertheless, Ga-67 scan has an important role in defining complete remission after treatment and therefore in planning subsequent treatment. Considering the lower costs of CT scan plus Ga-67 ($320) versus MR alone ($810), the two tests may be considered procedures of choice in staging as well as in restaging patients with Hodgkin's disease.

Original languageEnglish
JournalAnnals of Oncology
Volume8
Issue numberSUPPL. 1
Publication statusPublished - 1997

Fingerprint

Mediastinal Diseases
Gallium
Hodgkin Disease
Radionuclide Imaging
Magnetic Resonance Spectroscopy
Tomography
Drug Therapy
Cost-Benefit Analysis
Radiotherapy
Thorax
Therapeutics

Keywords

  • computed tomography
  • gallium scan
  • magnetic resonance
  • mediastinal Hodgkin's disease

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease. / Devizzi, L.; Maffioli, L.; Bonfante, V.; Viviani, S.; Balzarini, L.; Gasparini, M.; Valagussa, P.; Bombardieri, E.; Santoro, A.; Bonadonna, G.

In: Annals of Oncology, Vol. 8, No. SUPPL. 1, 1997.

Research output: Contribution to journalArticle

Devizzi, L. ; Maffioli, L. ; Bonfante, V. ; Viviani, S. ; Balzarini, L. ; Gasparini, M. ; Valagussa, P. ; Bombardieri, E. ; Santoro, A. ; Bonadonna, G. / Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease. In: Annals of Oncology. 1997 ; Vol. 8, No. SUPPL. 1.
@article{b0b4dbd55f7743ecaa5bd951578fb040,
title = "Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease",
abstract = "Background: In patients with Hodgkin's disease, the use of gallium-67 scintigraphy (Ga-67) compared to conventional staging and restaging techniques is still controversial. In particular in a combined modality treatment with chemotherapy and radiotherapy given in sequence, its role in detecting active disease after chemotherapy may be useful in planning the subsequent radiotherapeutic strategy. Patients and methods: From March 1990 to September 1994, 125 patients with previously untreated histologically proven Hodgkin's disease were enrolled in two different prospective trials according to clinical stage. Staging procedures included Ga-67, chest- abdominal computed tomography (CT), and/or magnetic resonance (MR). All three tests were performed in 53 patients at staging and in 47 at restaging. Results of Ga-67 at staging were compared to conventional procedures or pathological findings. Results of Ga-67, CT scan, and MR at restaging were compared to disease outcome during the follow-up. Finally a cost/benefit ratio for each test was determined. Results: At staging, Ga-67 showed lower sensitivity than CT and MR (90 vs. 96 and 100{\%}, respectively) because of the number of false-negative images. Nevertheless, by using both CT and Ga-67 scan, the sensitivity is equal to that observed with MR (100{\%}). At restaging, Ga-67 is superior to CT scan and equivalent to MR in detecting true negative patients (specificity: 98{\%} vs. 45{\%} vs. 92{\%}). Conclusion: As a single technique, Ga-67 scan cannot substitute for CT scan or MR in staging patients with Hodgkin's disease. Nevertheless, Ga-67 scan has an important role in defining complete remission after treatment and therefore in planning subsequent treatment. Considering the lower costs of CT scan plus Ga-67 ($320) versus MR alone ($810), the two tests may be considered procedures of choice in staging as well as in restaging patients with Hodgkin's disease.",
keywords = "computed tomography, gallium scan, magnetic resonance, mediastinal Hodgkin's disease",
author = "L. Devizzi and L. Maffioli and V. Bonfante and S. Viviani and L. Balzarini and M. Gasparini and P. Valagussa and E. Bombardieri and A. Santoro and G. Bonadonna",
year = "1997",
language = "English",
volume = "8",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease

AU - Devizzi, L.

AU - Maffioli, L.

AU - Bonfante, V.

AU - Viviani, S.

AU - Balzarini, L.

AU - Gasparini, M.

AU - Valagussa, P.

AU - Bombardieri, E.

AU - Santoro, A.

AU - Bonadonna, G.

PY - 1997

Y1 - 1997

N2 - Background: In patients with Hodgkin's disease, the use of gallium-67 scintigraphy (Ga-67) compared to conventional staging and restaging techniques is still controversial. In particular in a combined modality treatment with chemotherapy and radiotherapy given in sequence, its role in detecting active disease after chemotherapy may be useful in planning the subsequent radiotherapeutic strategy. Patients and methods: From March 1990 to September 1994, 125 patients with previously untreated histologically proven Hodgkin's disease were enrolled in two different prospective trials according to clinical stage. Staging procedures included Ga-67, chest- abdominal computed tomography (CT), and/or magnetic resonance (MR). All three tests were performed in 53 patients at staging and in 47 at restaging. Results of Ga-67 at staging were compared to conventional procedures or pathological findings. Results of Ga-67, CT scan, and MR at restaging were compared to disease outcome during the follow-up. Finally a cost/benefit ratio for each test was determined. Results: At staging, Ga-67 showed lower sensitivity than CT and MR (90 vs. 96 and 100%, respectively) because of the number of false-negative images. Nevertheless, by using both CT and Ga-67 scan, the sensitivity is equal to that observed with MR (100%). At restaging, Ga-67 is superior to CT scan and equivalent to MR in detecting true negative patients (specificity: 98% vs. 45% vs. 92%). Conclusion: As a single technique, Ga-67 scan cannot substitute for CT scan or MR in staging patients with Hodgkin's disease. Nevertheless, Ga-67 scan has an important role in defining complete remission after treatment and therefore in planning subsequent treatment. Considering the lower costs of CT scan plus Ga-67 ($320) versus MR alone ($810), the two tests may be considered procedures of choice in staging as well as in restaging patients with Hodgkin's disease.

AB - Background: In patients with Hodgkin's disease, the use of gallium-67 scintigraphy (Ga-67) compared to conventional staging and restaging techniques is still controversial. In particular in a combined modality treatment with chemotherapy and radiotherapy given in sequence, its role in detecting active disease after chemotherapy may be useful in planning the subsequent radiotherapeutic strategy. Patients and methods: From March 1990 to September 1994, 125 patients with previously untreated histologically proven Hodgkin's disease were enrolled in two different prospective trials according to clinical stage. Staging procedures included Ga-67, chest- abdominal computed tomography (CT), and/or magnetic resonance (MR). All three tests were performed in 53 patients at staging and in 47 at restaging. Results of Ga-67 at staging were compared to conventional procedures or pathological findings. Results of Ga-67, CT scan, and MR at restaging were compared to disease outcome during the follow-up. Finally a cost/benefit ratio for each test was determined. Results: At staging, Ga-67 showed lower sensitivity than CT and MR (90 vs. 96 and 100%, respectively) because of the number of false-negative images. Nevertheless, by using both CT and Ga-67 scan, the sensitivity is equal to that observed with MR (100%). At restaging, Ga-67 is superior to CT scan and equivalent to MR in detecting true negative patients (specificity: 98% vs. 45% vs. 92%). Conclusion: As a single technique, Ga-67 scan cannot substitute for CT scan or MR in staging patients with Hodgkin's disease. Nevertheless, Ga-67 scan has an important role in defining complete remission after treatment and therefore in planning subsequent treatment. Considering the lower costs of CT scan plus Ga-67 ($320) versus MR alone ($810), the two tests may be considered procedures of choice in staging as well as in restaging patients with Hodgkin's disease.

KW - computed tomography

KW - gallium scan

KW - magnetic resonance

KW - mediastinal Hodgkin's disease

UR - http://www.scopus.com/inward/record.url?scp=8244233157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8244233157&partnerID=8YFLogxK

M3 - Article

C2 - 9187430

AN - SCOPUS:8244233157

VL - 8

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 1

ER -